PT Kalbe Farma Tbk. (PTKFF)
OTCMKTS
· Delayed Price · Currency is USD
0.0751
+0.0101 (15.54%)
At close: Mar 26, 2025
PT Kalbe Farma Tbk. Revenue
In the year 2024, PT Kalbe Farma Tbk. had annual revenue of 32.63T IDR with 7.16% growth. PT Kalbe Farma Tbk. had revenue of 8.39T in the quarter ending December 31, 2024, with 6.35% growth.
Revenue
32.63T IDR
Revenue Growth
+7.16%
P/S Ratio
1.70
Revenue / Employee
2.53B IDR
Employees
12,903
Market Cap
3.45B USD
Revenue Chart
* This company reports financials in IDR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.63T | 2,178.64B | 7.16% |
| Dec 31, 2023 | 30.45T | 1,515.63B | 5.24% |
| Dec 31, 2022 | 28.93T | 2,672.31B | 10.18% |
| Dec 31, 2021 | 26.26T | 3,148.54B | 13.62% |
| Dec 31, 2020 | 23.11T | 479.18B | 2.12% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 20.65M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.38M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |